Biogenerics In Holding Pattern As Legislation And Election Campaigns Simmer
Executive Summary
The pending introduction of follow-on biologics legislation by Reps. Anna Eshoo, D-Calif., and Joe Barton, R-Texas, will likely help parties in the debate gauge the strength of their positions
You may also be interested in...
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs
Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer
It was not a pretty sight in Room 2123 of the Rayburn House Office Building on Feb. 12, where the House's Energy and Commerce Committee's Oversight and Investigations Subcommittee held a hearing on fraud in the studies of the antibiotic Ketek. The head of Sanofi-Aventis' U.S. R&D had to acknowledge he could not verify that other studies were free from fraud, and committee members lambasted FDA Commissioner Andrew von Eschenbach in absentia